BMY

AstraZeneca, Bristol Myers Squibb in talks on $400 billion megadeal

British pharmaceutical giant AstraZeneca is in talks to merge with U.S. rival Bristol Myers Squibb in a deal that could be valued near $400 billion, the Financial Times reported. A combination would create one of the largest drugmakers in the world, reshaping the competitive landscape across cancer, immunology and cardiovascular treatments.